Benidipine is a dihydropyridine calcium channel blocker for the treatment of
high blood pressure (hypertension). It is a triple
L-,
T-, and
N-type
calcium channel blocker. It is reno- and cardioprotective.
It was patented in 1981 and approved for medical use in 1991.
Dosing
Benidipine is dosed as 2–8 mg once daily.
Mechanism
Benidipine is a
calcium channel blocker.
Benidipine has additionally been found to act as an
antagonist of the
mineralocorticoid receptor
The mineralocorticoid receptor (or MR, MLR, MCR), also known as the aldosterone receptor or nuclear receptor subfamily 3, group C, member 2, (NR3C2) is a protein that in humans is encoded by the ''NR3C2'' gene that is located on chromosome 4q31 ...
, or as an
antimineralocorticoid
An antimineralocorticoid, also known as a mineralocorticoid receptor antagonist (MRA or MCRA) or aldosterone antagonist, is a diuretic drug which antagonizes the action of aldosterone at mineralocorticoid receptors. This group of drugs is ofte ...
.
Names
Other names include Benidipinum or benidipine hydrochloride.
Benidipine is sold as Coniel by Kyowa Hakko Kogyo.
Benidipine is initially licensed for use in Japan and selected
Southeast Asian countries and later in Turkey, where it is sold as 4 mg tablets.
References
{{Mineralocorticoidics
Antimineralocorticoids
Aldosterone synthase inhibitors
Calcium channel blockers
Carboxylate esters
Dihydropyridines
Methyl esters
Nitrobenzenes
Piperidines